A single intraarticular injection of a tranexamic acid-modified hyaluronic acid (HA/TXA) alleviates pain and reduces OA development in a murine model of monosodium iodoacetate-induced osteoarthritis

IF 4.4 2区 医学 Q1 PHARMACOLOGY & PHARMACY Frontiers in Pharmacology Pub Date : 2024-09-11 DOI:10.3389/fphar.2024.1456495
Sybille Brochard, Karim Boumédiene, Jéromine Mercier, Véronique Agin, Thierry Conrozier, Catherine Baugé
{"title":"A single intraarticular injection of a tranexamic acid-modified hyaluronic acid (HA/TXA) alleviates pain and reduces OA development in a murine model of monosodium iodoacetate-induced osteoarthritis","authors":"Sybille Brochard, Karim Boumédiene, Jéromine Mercier, Véronique Agin, Thierry Conrozier, Catherine Baugé","doi":"10.3389/fphar.2024.1456495","DOIUrl":null,"url":null,"abstract":"RationaleTranexamic acid (TXA) is a strong and specific plasminogen activator inhibitor with inhibitory effects on the matrix metalloproteases involved in the pathophysiology of osteoarthritis (OA) through targeting of the fibrinolysis pathway. In this study, we evaluated the analgesic and chondroprotective effects of a HA-tranexamic acid (HA/TXA) conjugate, compared to HA alone and placebo, in an animal model of knee OA.MethodsKnee OA was induced in 15 C<jats:sup>5</jats:sup>7 b l/6J mice by IA injection of 0.75 mg of Monosodium IodoAcetate (MIA). At day 28, the mice received 1 IA injection of 10 µL of saline (control-group), or of HA or of HA/TXA. Tactile sensitivity was assessed using von Frey filaments. Stimulations started at 1 g and increased until a response was obtained (up to 4 g). A response to the stimulus was counted if the animal withdrew its paw. If the animal responded to the 1 g stimulation, stimulation was reduced until the lack of response was observed (up to 0.2 g). At day 56, mice were euthanized for knee histological assessment. Cartilage degradation was assessed using the OARSI score. Statistical analysis was performed on GraphPad Prism 8.0.2 software. Kruskal–Wallis or Mann-Whitney tests were performed as appropriate.ResultsJust before treatment administration, no intergroup difference in paw withdrawal threshold was observed. Throughout the experiment animals given saline and HA had a lower paw withdrawal threshold than those treated with HA/TXA (<jats:italic>p</jats:italic> &amp;lt; 0.01). In the control group OARSI score was 5.5 ± 0.6. In HA and HA + TXA treated mice the OARSI score was 3.2 ± 0.8 and 3.1 ± 0.5 (<jats:italic>p</jats:italic> &amp;lt; 0.01) showing that both treatments were able to reduce OA progression.ConclusionIn this animal model of MIA induced KOA, a single IA injection of a HA/TXA conjugate resulted in a greater efficacy on pain than both saline and HA. HA and HA/TXA exhibited chondroprotective effects compared to placebo.","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2024.1456495","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

RationaleTranexamic acid (TXA) is a strong and specific plasminogen activator inhibitor with inhibitory effects on the matrix metalloproteases involved in the pathophysiology of osteoarthritis (OA) through targeting of the fibrinolysis pathway. In this study, we evaluated the analgesic and chondroprotective effects of a HA-tranexamic acid (HA/TXA) conjugate, compared to HA alone and placebo, in an animal model of knee OA.MethodsKnee OA was induced in 15 C57 b l/6J mice by IA injection of 0.75 mg of Monosodium IodoAcetate (MIA). At day 28, the mice received 1 IA injection of 10 µL of saline (control-group), or of HA or of HA/TXA. Tactile sensitivity was assessed using von Frey filaments. Stimulations started at 1 g and increased until a response was obtained (up to 4 g). A response to the stimulus was counted if the animal withdrew its paw. If the animal responded to the 1 g stimulation, stimulation was reduced until the lack of response was observed (up to 0.2 g). At day 56, mice were euthanized for knee histological assessment. Cartilage degradation was assessed using the OARSI score. Statistical analysis was performed on GraphPad Prism 8.0.2 software. Kruskal–Wallis or Mann-Whitney tests were performed as appropriate.ResultsJust before treatment administration, no intergroup difference in paw withdrawal threshold was observed. Throughout the experiment animals given saline and HA had a lower paw withdrawal threshold than those treated with HA/TXA (p &lt; 0.01). In the control group OARSI score was 5.5 ± 0.6. In HA and HA + TXA treated mice the OARSI score was 3.2 ± 0.8 and 3.1 ± 0.5 (p &lt; 0.01) showing that both treatments were able to reduce OA progression.ConclusionIn this animal model of MIA induced KOA, a single IA injection of a HA/TXA conjugate resulted in a greater efficacy on pain than both saline and HA. HA and HA/TXA exhibited chondroprotective effects compared to placebo.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在碘乙酸钠诱导的骨关节炎小鼠模型中,一次性关节内注射氨甲环酸改性透明质酸(HA/TXA)可减轻疼痛并减少 OA 的发展
理论依据氨甲环酸(TXA)是一种强效特异性纤溶酶原激活剂抑制剂,可通过靶向纤溶途径抑制参与骨关节炎(OA)病理生理学的基质金属蛋白酶。在本研究中,我们在膝关节OA动物模型中评估了HA-氨甲环酸(HA/TXA)共轭物与单用HA和安慰剂相比的镇痛和软骨保护作用。第28天,小鼠接受一次10微升生理盐水(对照组)、HA或HA/TXA的IA注射。使用 von Frey 灯丝评估触觉灵敏度。刺激从 1 g 开始,逐渐增加直至出现反应(最多 4 g)。如果动物收回爪子,则算作对刺激有反应。如果动物对 1 克的刺激有反应,则减少刺激,直到观察到无反应为止(最多 0.2 克)。第 56 天,小鼠安乐死,以进行膝关节组织学评估。使用 OARSI 评分评估软骨退化情况。统计分析在 GraphPad Prism 8.0.2 软件中进行。结果就在给药前,没有观察到爪退缩阈值的组间差异。在整个实验过程中,接受生理盐水和 HA 治疗的动物的爪退缩阈值低于接受 HA/TXA 治疗的动物(p &lt;0.01)。对照组的 OARSI 评分为 5.5 ± 0.6。HA和HA + TXA治疗组小鼠的OARSI评分分别为3.2 ± 0.8和3.1 ± 0.5(pamp &;lt;0.01),这表明两种治疗方法都能减少OA的进展。与安慰剂相比,HA和HA/TXA具有保护软骨的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Pharmacology
Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.80
自引率
8.90%
发文量
5163
审稿时长
14 weeks
期刊介绍: Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
期刊最新文献
The glucocorticoid dose-mortality nexus in pneumonia patients: unveiling the threshold effect. The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab. The role of TRPV1 in chronic prostatitis: a review. Transcriptomics-based anti-tuberculous mechanism of traditional Chinese polyherbal preparation NiuBeiXiaoHe intermediates. Applications and challenges of photodynamic therapy in the treatment of skin malignancies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1